Amy Ryan's practice focuses on technology related transactions. Ms. Ryan regularly assists clients with drafting and negotiating a broad range of contracts for the commercialization and protection of intellectual property and technology. Her experience in this capacity includes drafting and negotiating license agreements, development agreements, collaboration agreements, clinical study agreements, technology transfer agreements, and manufacturing and distribution agreements. While Ms. Ryan counsels clients in a variety of industries, she concentrates in the field of life sciences and has particular expertise in representing both commercial and non-profit entities in novel research collaborations with academic and medical research institutions.

Ms. Ryan is a 1999 cum laude graduate of the Georgetown University Law Center, where she was a Project Editor for the Georgetown Law Journal.

Experience

  • The Parker Institute for Cancer Immunotherapy in its establishment of a US$250 million cancer immunotherapy research consortium comprised of six academic and medical research institutions, including a novel, collaborative approach to centralized tech transfer and commercialization processes across participating institutions.
  • The Sean N. Parker Foundation in its US$24 million gift to Stanford University for the establishment of the Sean N. Parker Center for Allergy and Asthma Research at Stanford.
  • The Lieber Institute for Brain Development in its formation and affiliation with Johns Hopkins University; developed intellectual property, publications, and conflicts policies for the institute; advised on material transfers, licenses, and collaborations with other researchers and private companies. 
  • The Juvenile Diabetes Research Foundation in its development and implementation of an intellectual property policy with nine (9) university and academic medical center grant recipients involved in the Artificial Pancreas Project.
  • In a transaction recognized by the Licensing Executives Society as a Deal of Distinction ™, a leading global pharmaceutical company in a pioneering drug discovery and development collaboration with a major US university. The deal was cited as being an innovative and "excellent illustration of the interface between industry and academia."

  • A leading US biopharmaceutical company in its negotiations with a major medical center to develop a strategic alliance that will design and conduct clinical trials for oncology product candidates.

Perspectives

Managing Your Grant Support
AUTM 2018, Phoenix, AZ
Life Sciences Transactions Boot Camp
Arnold & Porter Kaye Scholer, Morristown, NJ
Cornerstones of Collaboration: Foundation-led Partnerships to Accelerate R&D
FasterCures Workshop, New York, NY
Contracts for Nonprofits: Avoiding Landmines and Pitfalls
Arnold & Porter LLP, Insights for Nonprofit Organization Series, Washington, DC
Under Contract (pdf)

International Clinical Trials

More

Credentials

Education
  • JD, Georgetown University Law Center, 1999, cum laude
  • BA, University of Virginia, 1988
Admissions
  • District of Columbia
Overview

Email Disclaimer